- Home
- AMPY vs IMUX Comparison
AMPY vs IMUX Comparison
Compare AMPY & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMPY | IMUX |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.9M | 209.2M |
| IPO Year | 2011 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AMPY | IMUX |
|---|---|---|
| Price | $3.87 | $13.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 602.3K | 136.2K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.26 | 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,637,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.41 | $0.51 |
| 52 Week High | $6.79 | $15.84 |
Technical Indicators
Market Signals| Indicator | AMPY | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 47.01 |
| Support Level | $3.86 | $12.73 |
| Resistance Level | $4.22 | $15.82 |
| Average True Range (ATR) | 0.16 | 0.91 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 40.91 | 38.01 |
Price Performance
Historical ComparisonAbout AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The companies oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.